Literatura académica sobre el tema "Treatment-Resistant Depression (TRD)"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Treatment-Resistant Depression (TRD)".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Treatment-Resistant Depression (TRD)"
Gałecki, Piotr, Jerzy Samochowiec, Magdalena Mikułowska y Agata Szulc. "Treatment-Resistant Depression in Poland—Epidemiology and Treatment". Journal of Clinical Medicine 11, n.º 3 (18 de enero de 2022): 480. http://dx.doi.org/10.3390/jcm11030480.
Texto completoBrenner, Philip, Johan Reutfors, Michel Nijs y Therese M.-L. Andersson. "Excess deaths in treatment-resistant depression". Therapeutic Advances in Psychopharmacology 11 (enero de 2021): 204512532110065. http://dx.doi.org/10.1177/20451253211006508.
Texto completoKasper, Siegfried y Alan Frazer. "Editorial for Treatment-Resistant Depression (TRD)". International Journal of Neuropsychopharmacology 22, n.º 2 (1 de febrero de 2019): 83–84. http://dx.doi.org/10.1093/ijnp/pyz006.
Texto completoBonner, Deirdre y Robert Howard. "Treatment-Resistant Depression in the Elderly". International Psychogeriatrics 7, S1 (octubre de 1995): 83–94. http://dx.doi.org/10.1017/s1041610295002377.
Texto completoPETERSEN, T., J. A. GORDON, A. KANT, M. FAVA, J. F. ROSENBAUM y A. A. NIERENBERG. "Treatment resistant depression and Axis I co-morbidity". Psychological Medicine 31, n.º 7 (octubre de 2001): 1223–29. http://dx.doi.org/10.1017/s0033291701004305.
Texto completoPetersen, Timothy, George I. Papakostas, Yasmin Mahal, Wendy M. Guyker, Erin C. Beaumont, Jonathan E. Alpert, Maurizio Fava y Andrew A. Nierenberg. "Psychosocial functioning in patients with treatment resistant depression". European Psychiatry 19, n.º 4 (junio de 2004): 196–201. http://dx.doi.org/10.1016/j.eurpsy.2003.11.006.
Texto completoKolar, D. "Treatment-Resistant Depression – What is the Effective Maintenance Treatment". European Psychiatry 65, S1 (junio de 2022): S555—S556. http://dx.doi.org/10.1192/j.eurpsy.2022.1422.
Texto completoMillet, E., R. Icick y J. P. Lépine. "Treatment-resistant depression: From pseudo-resistance to full resistance". European Psychiatry 26, S2 (marzo de 2011): 638. http://dx.doi.org/10.1016/s0924-9338(11)72344-6.
Texto completoRannanpää, S., H. Taipale, A. Tanskanen, M. Lähteenvuo, S. Huoponen y J. Tiihonen. "Healthcare costs and productivity losses in treatment-resistant depression in Finland". European Psychiatry 65, S1 (junio de 2022): S268. http://dx.doi.org/10.1192/j.eurpsy.2022.686.
Texto completoMacewan, G. William y Ronald A. Remick. "Treatment Resistant Depression: A Clinical Perspective*". Canadian Journal of Psychiatry 33, n.º 9 (diciembre de 1988): 788–92. http://dx.doi.org/10.1177/070674378803300902.
Texto completoTesis sobre el tema "Treatment-Resistant Depression (TRD)"
Cuomo, Alessandro. ""TREATMENT-RESISTANT DEPRESSION" AND USE OF INTRAVENOUS KETAMINE AND INTRANASAL ES-KETAMINE". Doctoral thesis, Università di Siena, 2021. http://hdl.handle.net/11365/1148507.
Texto completoFerri, Giovanni. "Study on hippocampal brain volumes in treatment resistant depression during vagal nerve stimulation (VNS)". Doctoral thesis, Università degli studi di Padova, 2011. http://hdl.handle.net/11577/3421693.
Texto completoPREMESSE: Modifiche nella volumetria delle strutture limbiche-paralimbiche coinvolte nella regolazione del tono dell’umore sono state descritte nella letteratura più recente sui Disturbi Depressivi Maggiori (DDM). Una diminuzione nei volumi della sostanza grigia ippocampale è uno dei possibili meccanismi coinvolti nella patogenesi della depressione [Nifosì et al. 2010]. Evidenze convergenti sembrano confermare che in corso di depressione una ridotta neurogenesi possa verificarsi in questa area e che una modulazione positiva di tale processo sia fondamentale per l’azione antidepressiva. La Neurogenesi è stimolata sia da stimoli che rafforzano la plasticità neuronale (come stimolazioni ambientali esterne, esercizio fisico, stimolazione elettrica) sia dai trattamenti antidepressivi. In studi di neuroimaging funzionale, la Stimolazione del Nervo Vago, (VNS) una metodica di recente introduzione per il trattamento della Depressione farmaco Resistente (TRD), è stata dimostrato che la sua azione antidepressiva può essere correlata con modifiche nel flusso ematico cerebrale nella corteccia limbica e prefrontale [Zobel et al 2005]. Obiettivo di questo studio è valutare se modifiche delle volumetrie in specifiche aree coinvolte nella depressione, possano essere ottenuta mediante la VNS. METODOLOGIA: E’ stato effettuato un confronto dei dati sulle modifiche di volume di specifiche regioni d’interesse in 6 pazienti con depressione farmaco resistente trattati mediante VNS (VNS Therapy System™, Cyberonics, Houston, Texas –USA) con i volumi delle stesse aree in 5 casi di TRD trattati in maniera convenzionale. Le Risonanze Magnetiche Nucleari (MRI) cerebrali sono state realizzate prima dell’impianto (t0 ) e dopo 12 mesi( t1). L’entità della depressione è stata valutata mediante scale autosomministrate (BDI ) o etero somministrate (HDRS) ogni tre mesi durante il del monitoraggio clinico. RISULTATI: Tre dei sei pazienti che hanno ricevuto la VNS hanno manifestato una buona risposta clinica (riduzione dei punteggi alle scale per la depressione > 50% dai punteggi iniziali) a tre mesi dall’inizio del trattamento. Un aumento significativo di circa il 22% e del 14% rispettivamente per ippocampo sinistro e destro è stato messo in luce dopo un anno di trattamento mediante VNS. Nessuna correlazione è stata trovata tra le principali variabili indicative dell’andamento clinico e l’aumento dei volumi cerbrali. I pazienti non responsivi alla VNS non hanno manifestato aumenti nei volumi ippocampali. I dati preliminari riscontrati in questo piccolo gruppo sembrano confermare il ruolo fondamentale del rimodellamento ippocampale come marker per la possibile risposta clinica nella TRD.
Arildsson, Mathilda. "Har ketamin effekt mot terapiresistent depression?" Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-81676.
Texto completoDepression is a syndrome characterized by depressed mood, loss of interest and energy, feelings of guilt or worthlessness and thoughts of death and suicide. Over 300 million people suffer from depression and it is one of the leading causes of disability in the world. Today’s treatment for depression includes psychological treatment as well as pharmacological treatment. While there are many antidepressant drugs, it can take up to weeks or even months before a clinical effect in the severity of the depression can be noticed. In addition, one third of the patients do not achieve remission. These patients, after treatment with two antidepressant medications given at adequate doses for an adequate duration, are considered to have treatment-resistant depression (TRD). Ketamine is a drug long used for its anesthetic and analgesic effects, but it is also known as a party-drug that can cause out-of-body experience. However, it has also been found that a single-dose ketamine may give people with TRD a rapid antidepressant effect, within 24 hours. In contrast to current antidepressant medications which primarily acts on the monoaminergic system, ketamine instead acts on the glutamatergic system. The aim of this study was to evaluate if ketamine has an effect on people suffering from TRD. This study is a literature review where five randomized controlled trials on the effect of ketamine in patients with TRD have been analyzed. Four studies evaluated the effect of intravenous ketamine where one of them used a varied dose frequency and one of them used esketamine in various doses. The fifth study evaluated the effect of intranasal administration of ketamine. All studies were found in the database PubMed. The overall result shows that ketamine has an effect on TRD. After 24 hours all the studies showed a significant improvement in the severity of the depression with ketamine treatment compared to placebo (p <0.05). Ketamine treatment resulted in a 7-16 points larger reduction in depressive symptoms on the scales used compared to placebo. This represents on average a change from severe/moderately severe depression to mild depression. There was also a significant difference in response (at least 50 % reduction in points from baseline on the scale used) after 24 hours with ketamine treatment compared to placebo (p <0.05). The proportion of ketamine treated patients with response varied between 44-71 % compared to 0-6 % for placebo and 28 % for active placebo (midazolam). Even though ketamine seems to have an effect on patients with TRD there is still limited knowledge of how the antidepressant effect shall be maintained and the safety of long-term use. Further studies are needed to determine if ketamine will be an option in future antidepressant treatment against TRD.
Libros sobre el tema "Treatment-Resistant Depression (TRD)"
Lam, Raymond W. Depression. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198804147.001.0001.
Texto completoHowland, Robert H. Multidisciplinary Treatments and Medications for Depressive Disorders and Comorbidity. Editado por C. Steven Richards y Michael W. O'Hara. Oxford University Press, 2014. http://dx.doi.org/10.1093/oxfordhb/9780199797004.013.008.
Texto completoGoodman, Wayne K. y Mark S. George. Neuromodulation and Psychiatric Disorders. Editado por Dennis S. Charney, Eric J. Nestler, Pamela Sklar y Joseph D. Buxbaum. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190681425.003.0010.
Texto completoCapítulos de libros sobre el tema "Treatment-Resistant Depression (TRD)"
Selek, Salih y Jair C. Soares. "Neurobiology and Evidence-Based Review on Novel Therapeutic Strategy for Treatment-Resistant Depression (TRD)". En Understanding Depression, 269–75. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-6577-4_19.
Texto completo"Depression: Treatment-Resistant (TRD)". En The APRN and PA’s Complete Guide to Prescribing Drug Therapy. New York, NY: Springer Publishing Company, 2019. http://dx.doi.org/10.1891/9780826179357.0097b.
Texto completoLam, Raymond W. "Special populations". En Depression, 95–112. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198804147.003.0010.
Texto completoHoltzheimer, Paul E. y Helen Mayberg. "Subcallosal cingulate deep brain stimulation for treatment-resistant depression". En Landmark Papers in Psychiatry, editado por Elizabeth Ryznar, Aderonke B. Pederson, Mark A. Reinecke y John G. Csernansky, 311–26. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198836506.003.0019.
Texto completoActas de conferencias sobre el tema "Treatment-Resistant Depression (TRD)"
Zöllner, R., M. Bopp, P. Dietsche, H. Rekate, B. Dietsche, A. Krug, B. Hanewald, O. Steinsträter, J. Sommer y M. Zavorotnyy. "Structural and metabolic changes in the anterior cingulate cortex (ACC) after treatment with repetitive transcranial magnetic stimulation (rTMS) in patients with treatment-resistant unipolar depression (TRD)". En Abstracts of the 30th Symposium of the AGNP. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1606408.
Texto completoWadkar, Abhijeet, Prithvi K. Jupalli y Samuel F. Asokanthan. "Simulation of Magnetic Field Induced Current for Magnetic Seizure Therapy". En ASME 2017 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/imece2017-72671.
Texto completo